Absolute Rules for Malignant Proliferating Trichilemmal Cyst: Diagnosis and Treatment
The Malignant Proliferating Trichilemmal Cyst, also known as malignant proliferating pilar tumor, represents an extremely rare neoplasm derived from the hair follicle. The precise etiology remains unknown; however, the main hypothesis suggests that these malignant formations may originate from a previously benign trichilemmal cyst that progresses to a proliferative phase before acquiring malignant characteristics. It is postulated that factors such as trauma, chronic inflammation, and continuous tissue irritation could act as stimuli for this transformation from a benign to a malignant skin lesion.
To date, fewer than fifty clinical cases of malignant proliferating trichilemmal cysts have been documented in the medical literature.
Clinical Presentation and Characteristics of Malignant Proliferating Pilar Tumor
Generally, the first indication of malignancy manifests as the accelerated growth of a pre-existing nodular lesion on the scalp, which may or may not have been initially diagnosed as a proliferating trichilemmal cyst. It is important to note that this malignant entity can arise as a recurrence of a proliferating trichilemmal cyst that was previously excised.
Since it is the malignant analog of proliferating trichilemmal cysts, most of these lesions are located on the scalp, predominantly affecting women between the ages of 50 and 75. The size of these formations usually exceeds 5 cm, although cases reaching up to 25 cm in diameter have been reported. This large volume can induce significant compression and necrosis in the underlying tissues. In advanced stages, the presence of regional or distant metastases must be considered.
Histological Diagnostic Methods
The definitive diagnosis of malignant proliferating trichilemmal cyst must be based on histological findings obtained from a skin biopsy. The ideal procedure involves the complete excision of the lesion for subsequent detailed histopathological examination.
The use of specialized staining techniques is crucial to establish a clear differentiation between proliferating trichilemmal tumors in their benign form and the malignant variant. Key histological indicators of malignant transformation include the presence of abnormal mitosis, marked cellular pleomorphism, an infiltrative growth pattern, and aneuploidy. Furthermore, immunohistochemical studies have suggested that the expression of the CD34 protein may serve as an additional useful marker to distinguish malignant proliferating trichilemmal cyst from squamous cell carcinoma.
It is imperative to perform a careful differential diagnosis of malignant proliferating trichilemmal carcinoma with other skin tumors, such as squamous cell carcinoma, dermoid cysts, and cylindromas. Given its exceptional rarity and variations in historically used nomenclature, which often lead to misdiagnosis as squamous cell carcinoma, the true incidence and exact number of malignant proliferating trichilemmal cysts remain unknown.
Treatment Options for the Neoplasm
The recommended first-line therapeutic strategy consists of complete surgical excision, always ensuring a margin of normal tissue around the excised lesion. In cases where superior control of the surgical margin is required, Mohs micrographic surgery may be employed. Currently, there is no standardized consensus on the exact extent of normal tissue margins to resect.
Additionally, radiotherapy and/or chemotherapy may be considered for the treatment of established metastases or in lesions presenting a high intrinsic metastatic potential. It is essential to implement rigorous clinical follow-up in postoperative patients to monitor the appearance of local recurrences or the development of metastases. Malignant proliferating trichilemmal cysts have been reported to have a tendency to recur and metastasize in up to 30% of treated cases.
